Description: HST Global, a publically held biotechnology and wellness company, discovers and develops breakthroughs in supporting and treating metabolic disorders associated with cancer and other life threatening illnesses. HST Global's new and novel therapeutic approaches positively impact patients with disorders associated with late stage cancer who are in need of supportive well-tolerated treatments. Through its proprietary scientific platform, HST Global is developing therapies that address metabolic deficiencies, dysfunction, or disorders, and provides an alternative source of support for patients.
Home Page: www.hstglobal.com
150 Research Drive
Hampton,
VA
23666
United States
Phone:
757 766 6100
Officers
| Name | Title |
|---|---|
| Mr. Ronald R. Howell | Chairman, CEO, Pres & Interim CFO |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 17.3196 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |